Business Wire

numares’ Novel GFR Equation Allows Accurate Assessment of Renal Insufficiency in Proof of Concept

25.2.2021 14:10:00 EET | Business Wire | Press release

Share

Leading NMR diagnostics company numares recently published data showing that its novel, multi-marker approach to assess kidney function allowed for a more precise estimation of glomerular filtration rate (GFR) by a simple serum test. Named GFRNMR , the test provided metabolic characterization of renal dysfunction, by evaluating a group of metabolites. This “metabolite constellation” was comprised of myo-inositol, dimethylsulfone, valine, and creatinine, independently from age and sex. The test holds the potential for an improved assessment of kidney function, and deeper insights into kidney pathophysiology.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210225005061/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

numares uses “metabolite constellations”: a set of combined metabolic biomarkers evaluated by AI, to assess kidney function with serum-based GFRNMR test. (Graphic: Business Wire)

In this proof-of-concept study, published in the peer-reviewed journal Diagnostics1 , numares showed that a combination of multiple renal biomarkers, all with pathophysiological relevance, may overcome the diagnostic limitations of existing methods used to estimate GFR. This is a measure of kidney function used for assessment of metabolic renal dysfunction associated with chronic kidney disease.2

GFRNMR is based on numares’ metabolomics approach: a combination of multiple metabolites, forming a metabolite constellation, analyzed by advanced nuclear magnetic resonance (NMR) spectroscopy and evaluated by numares’ proprietary, AI-driven AXINON® diagnostic software. Following a targeted metabolomics approach, numares identified and combined the metabolites myo-inositol, dimethylsulfone, valine, and creatinine into a unique metabolite constellation, developing an algorithm which enables improved assessment of kidney function by a simple serum test.

The multi-marker algorithm was trained with 95 bio-banked serum samples and tested in 189 independent samples originated from Lyon/France, Gothenburg/Sweden, and Berlin/ Germany. The results were compelling: GFRNMR correlated better with measured GFR. Overall percentages of GFRNMR values matched, or more frequently exceeded those for commonly used, recommended eGFR equations.

“The outcome of this proof of concept surpassed equations used to estimate GFR which are recommended by KDIGO and commonly used to assess kidney function,” says Winton Gibbons, President – US and co-Chief Executive Officer of numares. “Subsequent to this proof of concept, we have been able to further refine our metabolite-based modeling, using a much broader set of samples. This newer model resulted in yet more promising data in a US-based validation study. In total, the GFRNMR approach is now validated in clinical studies with ~1,500 patient samples, and numares plans to submit the GFRNMR test for FDA Clearance in the first half 2021.“

1 Full article: Ehrich, J., et al., Serum myo-inositol, dimethyl sulfone, and valine in combination with creatinine allow accurate assessment of renal insufficiency. Diagnostics 2021, 11(2), 234; available at https://www.mdpi.com/2075-4418/11/2/234/htm

2 Current diagnostics in kidney function assessment:

Fifteen percent of U.S. adults (37 million people) are estimated to have chronic kidney disease (CKD)*. Evaluation of renal dysfunction includes estimation of glomerular filtration rate (eGFR) as the initial step and subsequent laboratory testing. Existing methods for eGFR with endogenous markers still present important drawbacks. As a result several eGFR equations have been developed but were commonly found to be insufficient to assess patients’ complex renal dysfunction and complications according to the stages of CKD.

* Source: https://www.cdc.gov/kidneydisease/publications-resources/2019-national-facts.html

About numares

numares AG, based in Regensburg, Germany, is a fast-growing innovative diagnostics company that applies machine learning to metabolomics data to develop advanced analytical tests for high-throughput use in clinical diagnostics. The AXINON® System employs advanced nuclear magnetic resonance (NMR) spectroscopy to evaluate metabolic constellations. Magnetic Group Signaling (MGS® ) is a proprietary technology that enables NMR for highly standardized and rapid throughput testing. Metabolic tests stand as an important pillar in precision medicine to address unmet needs in cardiovascular, kidney, liver, and neurological diseases. You will find more information at https://www.numares.com/

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

For further information please contact:
numares
Christiane Proll
Tel.: +49 941 280 949-14
E-Mail: christiane.proll@numares.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Man & Science Completes Implantation in ONFIELD First-in-Human Study of Miniaturised ONS System for Chronic Cluster Headache19.11.2026 09:00:00 EET | Press release

Man & Science, a Belgian-based medical device company specialised in miniaturised neurostimulation technologies, today announced that all ten patients have been implanted and activated in its ONFIELD first-in-human pilot study of a miniaturised occipital nerve stimulation (ONS) implant for cluster headache, and that early clinical responses are encouraging. The ONFIELD study is evaluating the safety and feasibility of the Man & Science implant in patients whose cluster headaches remain inadequately controlled despite available treatments. All ten patients planned for this stage of the study have now received the implant and are being followed by the participating clinical team. Early observations show reductions in attack frequency in the patients assessed to date. No serious adverse events related to the implant surgery or the device have been reported so far. A severe and difficult-to-treat neurological disorder Cluster headache is a severe neurological disorder characterised by recu

Ant International Launches Whale Orchestration Protocol Under MAS’ BLOOM Initiative to Connect Tokenised Money Market Funds and Tokenised Deposits19.11.2026 08:00:00 EET | Press release

Ant International today announced the launch of the Whale Orchestration Protocol, a major upgrade to its blockchain-based wholesale settlement platform, WhaleRTP. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261118947513/en/ Developed under the Monetary Authority of Singapore’s (MAS) BLOOM1 (Borderless, Liquid, Open, Online, Multi-currency) initiative, the protocol enables seamless Delivery-versus-Payment (DvP) transactions between tokenised deposits and tokenised money market funds. Through WhaleRTP, the Whale Orchestration Protocol enables secure and atomic settlement between tokenised deposits and tokenised money market funds, overcoming traditional fund settlement delays. This unlocks immediate liquidity for the company's real-time global treasury management, allowing idle capital to be deployed in real time. Ant International has already completed pilot transactions in partnership with DBS and Franklin Templeton, who

RSA Compliance Advisor Closes the Governance Gaps Between Audits19.11.2026 08:00:00 EET | Press release

RSA, the identity standard for government agencies, finance, and high-assurance organizations, today announced the general availability of RSA Compliance Advisor, a new capability within RSA® Governance & Lifecycle, the RSA identity governance and administration (IGA) solution, that maps identity governance controls directly to regulatory requirements and reports on compliance posture continuously. Governments and regulators keep raising the bar. GDPR, CJIS, HIPAA, NIST, and POPIA each carry hundreds of requirements, and new regulatory activity keeps adding more. Despite growing regulatory requirements, most compliance programs still confirm their posture the way they did a decade ago: quarterly reviews, annual certifications, manually built spreadsheets. This reactive, periodic assessment doesn’t account for access that changes every day in between. A program built on point-in-time checkpoints can look compliant on the day of the audit and still carry risk that never gets seen. RSA Co

NETS and Ant International Deepen Partnership to Empower Singapore’s Businesses for a Future in Agentic Commerce with Agentic Mobile Protocol19.11.2026 07:30:00 EET | Press release

Network for Electronic Transfers (NETS), Singapore’s leading payment services group, and Ant International are deepening their partnership to help businesses across Singapore reach new customers, simplify their operations and thrive in the era of agentic commerce by building a more connected mobile ecosystem well adapted to the AI era. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261118997808/en/ Lawrence Chan, Group CEO, NETS (L) and Peng Yang, CEO, Ant International (R) NETS and Ant International signed a Memorandum of Understanding (MOU) at the Singapore Fintech Festival 2026 to explore a collaboration that draws on NETS’ digital payments services and Ant International’s Agentic Mobile Protocol (AMP) as well as its full stack of AI-native solutions. The expanded partnership spans several areas of strategic cooperation: Bringing agentic commerce capabilities to businesses of all sizes across Singapore NETS will become th

SBC Medical Group Reports Cybersecurity Incidents in Japan19.11.2026 06:39:00 EET | Press release

SBC Medical Group Holdings Incorporated (Nasdaq: SBC) ("SBC Medical Group" or the "Company"), a provider of comprehensive management services to medical corporations and their clinics, today reported the occurrence of recent cybersecurity incidents involving customer information associated with certain clinics in Japan, along with the status of its response. Overview of the Incidents On November 16, 2026, unauthorized access occurred to certain databases within a website system managed and operated by SBC Medical Group, Ltd., the Company’s, Japanese subsidiary, in connection with its management services in Japan. The Company confirmed that an unauthorized third party accessed and extracted customer information. The method of intrusion and full scope remain under investigation. Based on current information, the information obtained and the number of affected customers are as follows: Category Types of information Individuals Period Basic personal information (without reservation or trea

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye